SCHEMBL13901488

SCHEMBL13901488

Bc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)C1(NC(C)=O)CCCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDPK1 O15530 6/20 0.58
▸ CDK2 P24941 1/20 0.58
▸ ULK1 O75385 3/20 0.57
▸ PDK1 Q15118 3/20 0.57
▸ ULK2 Q8IYT8 3/20 0.57
▸ TBK1 Q9UHD2 13/20 0.57
▸ STK17A Q9UEE5 3/20 0.57
▸ MARK3 P27448 3/20 0.57
▸ MARK4 Q96L34 3/20 0.57
▸ NUAK1 O60285 2/20 0.55
▸ IKBKE Q14164 1/20 0.55
▸ CGAS Q8N884 1/20 0.55
▸ TYK2 P29597 3/20 0.49
▸ AAK1 Q2M2I8 2/20 0.49
▸ MKNK2 Q9HBH9 2/20 0.49
▸ STK17B O94768 1/20 0.49
▸ SIK2 Q9H0K1 1/20 0.49
▸ AURKA O14965 1/20 0.48
▸ NTRK1 P04629 2/20 0.47
▸ BMPR2 Q13873 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13898272 0.91 PDPK1 (0.70) PDPK1CDK2ULK1PDK1ULK2
SCHEMBL13901444 0.89 ULK1 (0.65) PDPK1CDK2ULK1PDK1ULK2
SCHEMBL13901522 0.84 ULK1 (0.63) PDPK1CDK2ULK1PDK1ULK2
SCHEMBL13901489 0.82 ULK1 (0.68) PDPK1CDK2ULK1PDK1ULK2
SCHEMBL13901281 0.82 ULK1 (0.61) PDPK1CDK2ULK1PDK1ULK2
SCHEMBL13901264 0.81 TBK1 (0.65) PDPK1CDK2ULK1PDK1ULK2
SCHEMBL13901319 0.81 PDPK1 (0.60) PDPK1CDK2ULK1PDK1ULK2
SCHEMBL13901548 0.81 ULK1 (0.64) PDPK1CDK2ULK1PDK1ULK2
SCHEMBL13901450 0.81 ULK1 (0.66) PDPK1CDK2ULK1PDK1ULK2
SCHEMBL13901454 0.81 ULK1 (0.59) PDPK1CDK2ULK1PDK1ULK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504410-B2 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents SCHERING AKTIENGESELLSCHAFT (DE) 2009-03-17 — — US disclosed
Send feedback